DNA demethylating agents and chromatin-remodelling drugs: which, how and why?

Area of Science:

• Epigenetics
• Cancer Biology
• Pharmacology

Background:

• DNA hypermethylation in gene promoter regions causes transcriptional repression and gene silencing.
• Aberrant methylation patterns are common in cancer, often silencing tumor suppressor genes.
• Targeting methylation-mediated gene repression is a key strategy in cancer therapy design.

Purpose of the Study:

• To review drugs that interfere with DNA methylation-mediated gene repression.
• To discuss the properties and side effects of these anti-cancer drugs.
• To propose strategies for designing more specific and effective cancer therapeutics.

Main Methods:

• Review of two major drug classes: DNMT inhibitors and HDAC inhibitors.
• Analysis of drug mechanisms, including competition with cytosine or SAM, and direct DNMT inhibition.
• Examination of compounds inhibiting repressor complex subunits like HDACs.

Main Results:

• Two main drug groups targeting epigenetic modifications in cancer were identified: DNMT inhibitors and HDAC inhibitors.
• DNMT inhibitors act by competing with cytosine or S-adenosylmethionine (SAM) or directly on DNMTs.
• HDAC inhibitors target repressor complexes, including histone deacetylases.

Conclusions:

• Drugs targeting DNA methylation and associated epigenetic machinery offer promising avenues for cancer treatment.
• Understanding drug properties and side effects is crucial for optimizing therapeutic strategies.
• Further research can lead to the development of more specific and effective drugs for cancer prevention and treatment.